Zydus life science has achieved a significant regulatory milestone with the receipt of final approval from the United States Food and Drug Administration (USFDA) for its Dapagliflozin tablets. The approval covers both 5mg and 10mg tablet strengths, marking an important expansion of the company's presence in the US pharmaceutical market.

Regulatory Approval and Exclusivity Benefits

The USFDA's final approval enables Zydus Life Sciences to manufacture and market Dapagliflozin tablets in the United States. This diabetes medication represents a key addition to the company's portfolio of approved generic pharmaceuticals for the American market. With this approval, Zydus is eligible for 180 days of shared generic drug exclusivity for Dapagliflozin Tablets in both approved strengths.

Manufacturing and Market Opportunity

Dapagliflozin tablets will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad. The approval positions Zydus Life Sciences to compete in a substantial market segment, with the reference product Farxiga generating annual sales of $10.20 billion in the United States according to IQVIA MAT February data.

Drug Profile and Therapeutic Use

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. This therapeutic profile positions the medication as an important treatment option in diabetes management protocols.

Portfolio Expansion

This USFDA approval represents another step in Zydus Life Sciences' strategy to expand its generic pharmaceutical offerings in the US market. The group now has 436 approvals and has filed 505 ANDAs since commencing the filing process. The company continues to build its presence in key therapeutic areas, with diabetes medications representing an important segment given the growing patient population and treatment needs.

Zydus Lifesciences Limited has received significant relief in its ongoing GST matters, with the company announcing that a Rs. 41.77 million GST demand for financial year 2019-20 has been dropped following a favorable order from the Adjudication Authority in Gandhinagar. This positive development comes as the pharmaceutical company continues to navigate various tax-related challenges.

Recent GST Relief

The company announced that it received a favorable order dated March 24, 2026, from the Adjudication Authority, Gandhinagar, GST Department, resulting in the complete dropping of a Rs. 41.77 million GST demand for financial year 2019-20. The company informed both BSE Limited and National Stock Exchange of India Limited about this development through official communication dated April 7, 2026.

Voluntary Disclosure and Governance

In its official communication to BSE Limited, Zydus Lifesciences clarified that this event is not material as per regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and the materiality policy of the Company. The disclosure was made purely on a voluntary basis as good governance practice, demonstrating the company's commitment to transparency with stakeholders.

Ongoing GST Challenges

While celebrating this relief, Zydus Lifesciences continues to face other GST-related matters. The company had previously disclosed receiving a separate GST demand order worth Rs. 14.20 million from tax authorities, covering a five-year period from financial year 2019-20 to 2023-24. This demand was issued by the Assistant Commissioner, Central Goods and Services Tax, Division-Ambala, under section 74 of CGST/HGST Act, 2017.

The pending demand centers on the alleged reversal of inadmissible Input Tax Credit for the specified financial years. Input Tax Credit allows businesses to claim credit for taxes paid on inputs used in production, and authorities have questioned the admissibility of certain credits claimed by the company.

Company's Strategic Response

Zydus Lifesciences has demonstrated a proactive approach to managing its tax matters. For the pending Rs. 14.20 million demand, the company has expressed strong confidence in its position and announced its intention to file an appeal against the decision. The company believes it has strong merits to contest the order and expects no material financial impact from this matter.

Regulatory Compliance and Transparency

The company's communication was signed by Dhaval N. Soni, Company Secretary and Compliance Officer, maintaining compliance with stock exchange listing obligations. This transparency regarding tax matters helps investors make informed decisions while demonstrating the company's commitment to keeping stakeholders informed about significant developments that could impact its operations.